【摘要】

【摘要】：目的：分析心血管疾病患者合并睡眠障碍发生率焦虑抑郁的机制，为临床治疗心血管疾病合并睡眠障碍提供科学依据。
方法：选取2012年1月-2014年12月200例医院收诊心血管疾病患者，并应用睡眠障碍国际分类（ICSD）标准判断患者是否合并出现睡眠障碍，根据患者检测
结果分为观察组114例（心血管疾病合并睡眠障碍）与对照组86例（心血管疾病不合睡眠障碍），使用焦虑自评量表以及抑郁自评量表观察两组焦虑抑郁的发生率，并给予对症治疗和干预措施。
结果：观察组114例患者中有57例患者出现焦虑抑郁情绪，发生率为50.0%；对照组86例患者中有24例患者出现焦虑抑郁情绪，发生率为27.9%，两组之间的比较差异具有统计学意义（X2值为5.203，P＜0.05）。经过一段时间的治疗后，两组患者的临床症状均得到缓解，观察组与对照组的有效治疗率为87.7%（100/114）和89.5%（77/86），两组之间的差异无统计学意义。
结论：心血管疾病合并睡眠障碍患者发生焦虑抑郁的机率比单心血管疾病患者的机率更高，且通过观察发现，七叶皂苷钠联合丁咯地尔对于心血管疾病具有较好的治疗效果。

【Abstract】

Abstract: Objective: To analyze peripheral vertigo patients with sleep disorders incidence of anxiety and depression mechanism for the clinical treatment of peripheral vertigo with sleep disorders to provide a scientific basis.
Methods: Selected 200 cases of peripheral vertigo patients treated in the hospital from January 2012 to December 2014, And applied the International Classification of Sleep Disorders (ICSD) criteria to judge whether a merger occurs in patients with sleep disorders, according to test results were divided into observation group 114 cases (peripheral vertigo with sleep disorders) and the control group of 86 patients (peripheral vertigo substandard sleep disorders), using the anxiety scale and self-rating depression scale were observed incidence of anxiety and depression, and given symptomatic treatment and interventions..
Results: The 114 cases of patients in the observation group had 57 cases of patients with anxiety and depression, the rate was 50.0%; the control group of 86 patients, 24 cases of patients with anxiety and depression, the rate was 27.9%, between the two groups the difference was statistically significant (X2 is 5.203, P <0.05). After a period of treatment, the clinical symptoms of the two groups were eased, effective treatment and control groups was observed in 87.7% (100/114) and 89.5% (77/86), the difference between the two groups no Statistical significance.
Conclusion  : The peripheral vertigo in patients with sleep disorders anxiety and depression probability is higher than the probability of a single peripheral vertigo patient, and the observation that, aescinate sodium Joint Buflomedil for peripheral vertigo has a better therapeutic effect.